Nymox Pharmaceutical annual depreciation and amortization
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical Depreciation & Amortization Growth & History (NYMXF)
Nymox Pharmaceutical's depreciation and amortization was $1,000 for fiscal 2024.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $1,000 | −$10,000 | −90.91% |
| 2023 | 2023-12-31 | $11,000 | −$1,000 | −8.33% |
| 2022 | 2022-12-31 | $12,000 | $0 | 0.00% |
| 2021 | 2021-12-31 | $12,000 | $3,000 | +33.33% |
| 2020 | 2020-12-31 | $9,000 | $0 | 0.00% |
| 2019 | 2019-12-31 | $9,000 | $6,000 | +200.00% |
| 2018 | 2018-12-31 | $3,000 | $1,000 | +50.00% |
| 2017 | 2017-12-31 | $2,000 | −$2,000 | −50.00% |
| 2016 | 2016-12-31 | $4,000 | −$6.0M | −99.93% |
| 2015 | 2015-12-31 | $6.0M | — | — |
Nymox Pharmaceutical quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.24
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $3,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $2,000 | −$1,000 | −33.33% |
| Q1 2023 | 2023-03-31 | $3,000 | $0 | 0.00% |
| Q3 2022 | 2022-09-30 | $3,000 | $0 | 0.00% |
| Q2 2022 | 2022-06-30 | $3,000 | $0 | 0.00% |
| Q1 2022 | 2022-03-31 | $3,000 | $0 | 0.00% |
| Q3 2021 | 2021-09-30 | $3,000 | — | — |
| Q2 2021 | 2021-06-30 | $3,000 | — | — |
| Q1 2021 | 2021-03-31 | $3,000 | — | — |
Nymox Pharmaceutical depreciation and amortization trends
Over the last five fiscal years, Nymox Pharmaceutical's depreciation and amortization decreased from $9,000 to $1,000, a change of −$8,000. The latest reported quarter, Q4 2024, shows $0.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nymox Pharmaceutical source filings ↗